Navigation Links
WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
Date:5/5/2008

NATICK, Mass., May 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that a World Intellectual Property Organization (WIPO) arbitration panel has issued its ruling in an arbitration between the Company and Medinol, Ltd. Medinol, which had requested the arbitration pursuant to the 2005 settlement agreement between the companies, alleged that the Liberte(R) and TAXUS(R) Liberte(R) stents infringed various U.S. and European patents held by Medinol. The arbitrators ruled that the Boston Scientific stents do not infringe any of the Medinol patents.

Under the terms of the settlement agreement, Medinol has a right to appeal to another WIPO panel.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our products and intellectual property of third parties. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
3. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
4. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
5. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
6. Panelists Announced for 2007 Manufacturers Forum
7. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
8. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
9. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
10. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
11. Sensitech to Sponsor Panel Session at IQPC Cool Chain Europe 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... management and analytics solutions, today announced that its Anzo Smart Data Lake® ... 2017 Software & Information Industry Association (SIIA) CODiE Awards. , Cambridge Semantics’ ...
(Date:7/26/2017)... Brea, Ca (PRWEB) , ... July 25, 2017 ... ... labels, specialty converted media and software solutions that enable short-run digital printing, is ... GHS Chemical Labels and its free GHS Wizard online software available at ...
(Date:7/26/2017)... ... July 25, 2017 , ... The ... that its regenerative stem cell therapy has been used on more than 13,000 ... for horses with potentially fatal injuries to tendons and ligaments. , In 2003 ...
(Date:7/26/2017)... ... July 25, 2017 , ... Provia Laboratories ... in the preparation and development of human cells and tissues for therapeutic use. ... Food and Drug Administration’s (FDA) Current Good Manufacturing Practices (cGMP) guidelines and provides ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):